科伦博泰生物-B:SKB2641L肺癌III期成功 SKB105达成授权

中金公司
Dec 11, 2025

近日,公司宣布:1)TROP2 ADC芦康沙妥珠单抗(SKB264)联合帕博利珠单抗(Keytruda)1L治疗PD-L1 阳性非小细胞肺癌(NSCLC)的国内III期临床OptiTROP-Lung05 达到主要终点。2)公司与Crescent Biopharma达成合作,将ITGB6 ADCSKB105 海外权益以8,000 万美元首付款和高达12.5 亿美元的里程碑授予Crescent,并以2...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10